5 January 2016 - Swiss drug company Actelion expects an average annual per-patient price for its new pulmonary arterial hypertension medicine in the United States of $160,000 to $170,000, before rebates, Chief Operating Officer Otto Schwarz told analysts on Tuesday.

For more details, go to: http://www.reuters.com/article/us-actelion-pah-prices-idUSKBN0UJ1SQ20160105